rs113488022
|
|
|
0.050 |
GeneticVariation |
BEFREE |
The genetic analysis with whole-exome sequencing studies showed no differential mutations of CTNNB1 (β-catenin) and BRAF (V600E) between TC and NC subtypes, but there was a difference between adamantinomatous craniopharyngioma and papillary craniopharyngioma.
|
31200374 |
2019 |
rs121913377
|
|
|
0.050 |
GeneticVariation |
BEFREE |
The genetic analysis with whole-exome sequencing studies showed no differential mutations of CTNNB1 (β-catenin) and BRAF (V600E) between TC and NC subtypes, but there was a difference between adamantinomatous craniopharyngioma and papillary craniopharyngioma.
|
31200374 |
2019 |
rs113488022
|
|
|
0.050 |
GeneticVariation |
BEFREE |
BRAF V600E and CTNNB1 in papCP and adaCP samples were sequenced by next-generation sequencing and the Sanger method, and mRNA expression levels of Axin2 and BMP4 were evaluated by RT-PCR.
|
30074466 |
2018 |
rs113488022
|
|
|
0.050 |
GeneticVariation |
BEFREE |
BRAF V600E mutations render PCP susceptible to BRAF/MEK inhibitors, but effective targeted therapies are needed for ACP.
|
29509940 |
2018 |
rs113488022
|
|
|
0.050 |
GeneticVariation |
BEFREE |
In this study, we first evaluated BRAF V600E and CTNNB1 mutations in four and 14 cases of pCP and aCP, respectively, using high-resolution melting analysis followed by Sanger sequencing.
|
28840946 |
2018 |
rs121913377
|
|
|
0.050 |
GeneticVariation |
BEFREE |
BRAF V600E and CTNNB1 in papCP and adaCP samples were sequenced by next-generation sequencing and the Sanger method, and mRNA expression levels of Axin2 and BMP4 were evaluated by RT-PCR.
|
30074466 |
2018 |
rs121913377
|
|
|
0.050 |
GeneticVariation |
BEFREE |
In this study, we first evaluated BRAF V600E and CTNNB1 mutations in four and 14 cases of pCP and aCP, respectively, using high-resolution melting analysis followed by Sanger sequencing.
|
28840946 |
2018 |
rs121913377
|
|
|
0.050 |
GeneticVariation |
BEFREE |
BRAF V600E mutations render PCP susceptible to BRAF/MEK inhibitors, but effective targeted therapies are needed for ACP.
|
29509940 |
2018 |
rs113488022
|
|
|
0.050 |
GeneticVariation |
BEFREE |
The authors have previously shown high mutation rates of BRAF V600E in papillary craniopharyngioma and of CTNNB1 in adamantinomatous craniopharyngioma.
|
27903124 |
2016 |
rs121913377
|
|
|
0.050 |
GeneticVariation |
BEFREE |
The authors have previously shown high mutation rates of BRAF V600E in papillary craniopharyngioma and of CTNNB1 in adamantinomatous craniopharyngioma.
|
27903124 |
2016 |
rs111033566
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The percentage of N29I mutations in ACP patients was higher than that reported in other studies, while the percentage of N34S and AAT mutations in ACP and idiopathic CP patients was similar.
|
19657220 |
2009 |
rs111966833
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The P55S mutation was observed in one ICP and one ACP patient, and in three normal individuals.
|
15082592 |
2004 |
rs1223231582
|
|
|
0.010 |
GeneticVariation |
BEFREE |
One ACP patient (2.2%) was found to carry the most common mutation (N34S) of SPINK1 compared to none of the ALD patients (P=NS).
|
12939655 |
2003 |
rs17107315
|
|
|
0.010 |
GeneticVariation |
BEFREE |
One ACP patient (2.2%) was found to carry the most common mutation (N34S) of SPINK1 compared to none of the ALD patients (P=NS).
|
12939655 |
2003 |